Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an audit and supervisory committee, subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, to strengthen its corporate governance framework.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260210-04.pdf","jir_short_summary":"Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an audit and supervisory committee, subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, to strengthen its corporate governance framework.","jir_summary":"### Background and Purpose of the Transition\nKobayashi Pharmaceutical Co., Ltd. has decided to transition from a company with a board of auditors to a company with an audit and supervisory committee as part of the \"Fundamental Reform of Corporate Governance\" announced in the press release dated September 17, 2024 regarding measures to prevent recurrence. This aims to strengthen the supervisory functions of the Board of Directors and enhance management agility. Audit and supervisory committee members will be part of the Board of Directors to ensure clear separation between supervisory and executive functions.\n\n### Timing of the Transition and Future Measures\nThe transition to a company with an audit and supervisory committee is subject to approval at the Annual General Meeting of Shareholders scheduled for March 27, 2026. Details of executive appointments post-transition have already been disclosed separately in the \"Notice Regarding Executive Appointments Following the Transition to a Company with an Audit and Supervisory Committee.\" Amendments to the Articles of Incorporation will be announced once finalized.","jir_financial_highlights":"Scheduled Transition Date: 2026-03-27 (Unknown)\nTransition Details: From a company with a board of auditors to a company with an audit and supervisory committee (Unknown)\nEnhancement of the Board of Directors\u2019 Function: Strengthening supervisory functions and accelerating decision-making (Unknown)","jir_category":"","jir_hashtags":"#KobayashiPharmaceuticalCoLtd, #CorporateRestructuring, #CorporateGovernance","jir_key_figures":"Scheduled Transition Date: March 27, 2026 (subject to Annual General Meeting approval)\nTransition Details: From a company with a board of auditors to a company with an audit and supervisory committee\nBackground: Corporate governance reform based on recurrence prevention measures dated September 17, 2024","jir_meta_title":"Kobayashi Pharmaceutical Co., Ltd. to Transition to Company with Audit and Supervisory Committee in March 2026, Strengthening Governance","jir_meta_description":"Kobayashi Pharmaceutical Co., Ltd. plans to transition from a company with a board of auditors to a company with an audit and supervisory committee at the Annual General Meeting of Shareholders on March 27, 2026, aiming to strengthen management supervisory functions and accelerate decision-making.","jir_og_title":"Kobayashi Pharmaceutical Strengthens Governance through Transition to Company with Audit and Supervisory Committee","jir_og_description":"Transition scheduled at the March 27, 2026 shareholders meeting to a company with an audit and supervisory committee, reinforcing supervisory functions and promoting swift decision-making.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-27080","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n